Endonuclease Gs12-7MAX variant and gene editing system mediated by same
Through the development of the Gs12-7MAX variant, the problem of low editing efficiency of Cas12a endonuclease was solved, efficient genome site-directed modification was achieved, and higher gene editing activity and specificity were demonstrated.
Patent Information
- Application Number
- CN202411320266.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-20
AI Technical Summary
The existing Cas12a endonuclease has the problem of low editing efficiency in genome editing, which limits its application in the field of site-directed genome modification.
A Gs12-7MAX variant was developed by mutating the amino acid position 157 of Gs12-7 endonuclease from Glu to Arg, and establishing an efficient genome site-directed modification technology based on the CRISPR-Gs12-7MAX system.
The Gs12-7MAX variant significantly improves gene editing activity, achieves more efficient genome site-directed modification, has broad application prospects, and its CRISPR system performs better than existing systems in terms of specificity and efficiency.
Smart Images

Figure BDA0005053658540000081 
Figure BDA0005053658540000091 
Figure BDA0005053658540000101
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of genome editing, and specifically relates to a nuclease Gs12-7MAX variant and a gene editing system mediated by the variant. Background Art
[0002] The CRISPR / Cas system is widely used for genome site-specific modification, epigenetic, base and lead editing in human cells, animals and plants. The commonly used editing system is derived from CRISPR / Cas9 of Streptococcus pyogenes. In addition, Cas12a nucleic acid endonucleases, including AsCas12a from Acidaminococcus sp. and LbCas12a from Lachnospiraceae bacteriumND2006, are also often used for genome editing. The advantages of Cas12a endonuclease are as follows: First, it recognizes T-rich PAM target sites, expanding the genome editing targeting space; only a single short ~40 nucleotides (nt) CRISPR RNA (crRNA) is needed to specifically edit the target; it has RNase activity and can achieve multiple targeted editing through poly-crRNA transcript processing; in addition, studies have shown that Cas12a is more specific than SpCas9 and has lower off-target effects.
[0003] Although Cas12a nuclease has shown multiple advantages, it is currently still limited by low editing efficiency, so it is urgent to develop efficient technology based on Cas12a genome fixed-point modification. Based on this, the present invention further transforms mutants on the basis of Gs12-7 endonuclease (CN116144631A) identified by bioinformatics and experiments in the early stage, and develops Gs12-7MAX variants and mediated genome fixed-point modification technology. Summary of the invention
[0004] The present invention develops a Gs12-7MAX variant for the first time. After the 157th amino acid of the Gs12-7 nuclease is mutated from Glu to Arg, it has higher gene editing activity than the wild-type Gs12-7. The present invention also establishes an efficient genome site-specific modification technology mediated by the CRISPR-Gs12-7MAX system.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] A variant of endonuclease Gs12-7MAX, comprising the following proteins:
[0007] I. The Gs12-7MAX protein with the amino acid sequence shown in SEQ ID NO.1, relative to the wild-type Gs12-7 endonuclease, has the 157th amino acid mutated from Glu to Arg.
[0008] II. A protein having one or more amino acids substituted, deleted or added compared to the amino acid sequence shown in SEQ ID NO.1, and substantially retaining the biological function derived from the sequence.
[0009] The fusion protein comprises the above-mentioned endonuclease and a polypeptide connected to the N-terminus or C-terminus of the protein.
[0010] A polynucleotide encoding the above-mentioned endonuclease or a polynucleotide encoding the above-mentioned fusion protein. A vector or a host cell containing the polynucleotide.
[0011] The application of the above-mentioned nuclease in gene editing includes modifying genes in prokaryotic genomes, eukaryotic genomes or in vitro genes, knocking out genes, changing the expression of gene products, repairing mutations or inserting polynucleotides.
[0012] The CRISPR / Gs12-7MAX gene editing system includes the above-mentioned endonuclease, or fusion protein, or polynucleotide, or vector, or host cell. Further, it also includes a direct repeat sequence capable of binding to the above-mentioned endonuclease and a guide sequence crRNA capable of targeting a target sequence.
[0013] The technical solution of the present invention has the following main beneficial effects:
[0014] 1. The present invention provides for the first time a Gs12-7MAX variant with higher gene editing activity. Compared with the wild-type Gs12-7, the 157th amino acid is mutated from Glu to Arg.
[0015] 2. The present invention has developed a highly efficient gene editing technology mediated by the CRISPR / Gs12-7MAX system, which has broad application prospects in the field of genome site-specific modification. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 .Comparison of the genome editing activities of Gs12-7 and enAsCas12a-HF1 based on high-throughput sequencing strategy; A. Comparison of the gene editing activities of Gs12-7 and enAsCas12a-HF1 at a single site by RNP delivery strategy; B. Analysis and statistical comparison of the gene editing activities of Gs12-7 and enAsCas12a-HF1 based on the plasmid delivery strategy.
[0017] Figure 2.Based on the high-throughput sequencing strategy, the gene editing activities of two Gs12-7 variants against a single site were evaluated. They are: Gs12-7E157R (amino acid mutated from Glu to Arg at position 157), Gs12-7EGK (amino acid mutated from Glu to Arg at position 157, amino acid mutated from Gly to Arg at position 516, and amino acid mutated from Lys to Val at position 522); A. Schematic diagram of the amino acid mutation sites of the two Gs12-7 variants; B. Comparison of the gene editing activities of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1 against a single site; C. Statistical analysis and comparison of the gene editing activities of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1.
[0018] Figure 3 .Comparison of the gene editing activities of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1 in simultaneously editing multiple different sites based on high-throughput sequencing strategy; A. Comparison of the gene editing activities of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1 in simultaneously editing multiple different sites; B. Statistical analysis and comparison of the gene editing activities of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1 in simultaneously editing multiple sites.
[0019] Figure 4 .The distribution of gene editing Indels of Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF11 was detected based on high-throughput sequencing strategy; A. Distribution of gene editing Indels of Gs12-7E157R in HEK293T cells; B. Distribution of gene editing Indels of Gs12-7EGK in HEK293T cells; C. Distribution of gene editing Indels of enAsCas12a-HF1 in HEK293T cells.
[0020] Figure 5 .Evaluation of the specificity of Gs12-7E157R and enAsCas12a-HF1 based on a high-throughput sequencing strategy;A. Experimental detection of off-target sites predicted by Gs12-7E157R and enAsCas12a-HF1;B. Statistical analysis and comparison of the actual occurrence of Gs12-7E157R and enAsCas12a-HF1 at predicted off-target sites. DETAILED DESCRIPTION
[0021] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0022] Example 1. Evaluation of the genome editing activity of endonucleases Gs12-7 and enAsCas12a-HF1
[0023] This embodiment is directed to the endonuclease Gs12-7 (CN116144631A) developed by the inventor in the early stage, and the activity comparison evaluation is performed with the enAsCas12a-HF1 endonuclease with relatively high activity currently known. The expression vectors of these two endonucleases are co-transfected into HEK 293T cells with the corresponding crRNA expression vectors, respectively, and the crRNA paired with the target nucleic acid is used to guide the Gs12-7 or enAsCas12a nuclease to recognize and bind to the target gene, thereby stimulating genome cutting activity. First, cells are collected and genomic DNA is extracted, and then high-throughput sequencing is performed, and then the genome editing activity of the target site is analyzed using CRISPResso2 software (https: / / github.com / pinellolab / CRISPResso2 / releases).
[0024] The target genes selected in this embodiment are human DNMT1, EMX1, FANCF and RUNX1 genes, the PAM recognized by crRNA is TTTV, the corresponding crRNA sequence is shown in Table 1, and the underlined region is the target pairing region. They are respectively constructed into crRNA eukaryotic expression vectors.
[0025] Table 1. Names and corresponding sequences of crRNA
[0026] crRNA Sequence (5'-3') DNMT1-1 AAUUUCUACUAUUGUAGAUUCUGAUGGUCCAUGUCUGUUA EMX1-1 AAUUUCUACUAUUGUAGAUUGGGAGGCCUGGAGUCAUGGC EMX1-2 AAUUUCUACUAUUGUAGAUUUUAUUCCCAUAGGGAAGGGG FANCF-1 AAUUUCUACUAUUGUAGAUUAGUUGCCCAGAGUCAAGGAA RUNX1-1 AAUUUCUACUAUUGUAGAUUGCUCCGAAGGUAAAAGAAAU
[0027] First, the activity of Gs12-7 was compared with that of the known enAsCas12a-HF1 endonuclease by RNP delivery strategy. HEK 293T cells were plated when the confluency reached 70-80%, and the number of cells seeded in 12-well plates was 8×10 4 Cells / well were transfected 6-8h after plating. 1.25μg Gs12-7-NLS-tagged or enAsCas12a-HF1 protein and 625ng crRNA were incubated to form the RNP complex of Gs12-7 or enAsCas12a-HF1, and then incubated with 50μL opti-MEM and 2.6μL Cas9 plus TMMix the reagent to form solution 1; add 3 μL of CRISPR to 50 μL of opti-MEM TM The reagent was mixed to form solution 2. Solution 2 was added to solution 1 and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded, and the cells were resuspended in 100 μL PBS to extract the cell genome. PCR amplification was performed on the target site of transfected positive cells. The changes in the cut target bands were observed by T7EN1 restriction reaction and agarose gel electrophoresis to determine the genome editing activity of Gs12-7 and enAsCas12a-HF1 nucleases. The gene editing efficiency was further calculated by Image J. The template for the negative control was the genome of wild-type HEK 293T cells without any treatment.
[0028] Next, HEK 293T cells were plated when the confluency reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4 Cells / well. After 6-8 hours of plating, transfection was performed. 1 μg of Gs12-7 eukaryotic expression vector plenti-Gs12-7-puro or enAsCas12a-HF1 eukaryotic expression vector plenti-enAsCas12a-HF1-puro, 500 ng of different crRNA expression vectors plenti-U6-crRNA-zsGreen, and 10 μL of Jetprime regent were added to 200 μL Jetprime Buffer, mixed by pipetting, and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After 72 hours of culture at 37°C, the culture medium was discarded, and the cells were resuspended in 100 μL PBS to extract the genome of the cells. The target site of the transfected positive cells was PCR amplified to edit the sequence nearby. The PCR product was recovered and amplicon sequenced by Illumina Novaseq PE150, and the editing activity was analyzed by CRISPResso2.
[0029] The results are as follows Figure 1As shown in A, using RNP delivery cell genome editing experiments, it was found that both Gs12-7 and enAsCas12a-HF1 nucleases have high editing activity, and in the absence of enrichment of positive gene editing cells, the gene editing activity of Gs12-7 is about 30%, but relatively speaking, the editing activity of Gs12-7 nuclease is lower than that of enAsCas12a-HF1. In the plasmid delivery cell genome editing experiment, it was found that the average gene editing efficiency of Gs12-7 was 17.83%, while that of enAsCas12a-HF1 was 21.32%. It was found that the average gene editing efficiency of wild-type Gs12-7 for multiple sites was still significantly lower than that of enAsCas12a-HF1 nuclease ( Figure 1 B). In view of this, the present invention further mutates the amino acid sequence of Gs12-7 endonuclease to improve its genome editing activity.
[0030] Example 2. Comparison of genome editing activity of different variants of Gs12-7 and enAsCas12a-HF1 in HEK293T cells
[0031] This example prepared two variants of Gs12-7 ( Figure 2 A): (1) variant Gs12-7E157R, in which the amino acid at position 157 is mutated from Glu to Arg, and the amino acid sequence is shown in SEQ ID NO: 1; (2) Gs12-7EGK, in which the amino acid at position 157 is mutated from Glu to Arg, the amino acid at position 516 is mutated from Gly to Arg, and the amino acid at position 522 is mutated from Lys to Val, and the amino acid sequence is shown in SEQ ID NO: 3, and the genome editing ability of each variant at the cellular level was evaluated compared with the known enAsCas12a-HF1 nuclease.
[0032] In this embodiment, the Gs12-7E157R human codon optimized expression vector (nucleotide sequence as shown in SEQ ID NO: 2) plenti-Gs12-7E157R-puro, the Gs12-7EGK human codon optimized expression vector plenti-Gs12-7EGK-puro (nucleotide sequence as shown in SEQ ID NO: 4), and the enAsCas12a-HF1 expression vector, respectively, and the corresponding different crRNA expression vectors plenti-U6-crRNA-zsGreen, are co-transfected into HEK 293T cells, and the crRNA paired with the target nucleic acid is used to guide the Gs12-7E157R, Gs12-7EGK and enAsCas12a-HF1 proteins to recognize and bind to the target nucleic acid, thereby stimulating genome cutting activity. Finally, the cells are collected and the genomic DNA is extracted, and the editing activity of the target position is analyzed by high-throughput sequencing and using CRISPResso2.
[0033] In this embodiment, the target nucleic acids selected are human EMX1, FANCF and RUNX1 genes, the PAM is TTTV, and the corresponding crRNA design is shown in Table 2, and the underlined area is the targeting area.
[0034] Table 2. Names and corresponding sequences of crRNA
[0035] crRNA Sequence (5'-3') EMX1-3 AAUUUCUACUAUUGUAGAUUUCAUCUGUGCCCCUCCCUCC EMX1-4 AAUUUCUACUAUUGUAGAUUUGGUUGCCCACCCUAGUCAU FANCF-2 AAUUUCUACUAUUGUAGAUUGGCGGGGUCCAGUUCCGGGA RUNX1-2 AAUUUCUACUAUUGUAGAUUAGCCUCACCCCUCUAGCCCU
[0036] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4 Cells / well. Transfection was performed 6-8 hours after plating. 1 μg of Gs12-7E157R, Gs12-7EGK or known enhanced enAsCas12a-HF1 eukaryotic expression vector, 500 ng of single crRNA expression vector and 10 μL of Jetprimeregent were added to 200 μL Jetprime Buffer, and mixed by pipetting. Incubate at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded, the cells were resuspended with 100 μL PBS and the genome of the cells was extracted. The target site of the transfected positive cells was PCR amplified to edit the sequence nearby. The PCR product was recovered and the amplicon was sequenced by Illumina Novaseq PE150, and the editing activity was analyzed by CRISPResso2.
[0037] The results are as follows Figure 2As shown, it was found that both Gs12-7E157R and Gs12-7EGK had genome editing activity. In the absence of enrichment of positive gene-edited cells, Gs12-7E157R could reach a maximum editing activity of about 42%, while the gene editing activity of Gs12-7EGK was lower, which was only about 28% ( Figure 2 B). Further testing found that the gene editing activity of Gs12-7E157R was higher than that of enAsCas12a-HF1 ( Figure 2 B), statistical analysis found that the average editing efficiency of the Gs12-7E157R variant can reach about 30%, which is significantly higher than the currently known enhanced enAsCas12a-HF1 ( Figure 2 C). In comparison, the Gs12-7E157R variant was found to have the highest genome editing activity, so it was named Gs12-7MAX.
[0038] Example 3. Comparison of the gene editing activities of Gs12-7MAX, Gs12-7EGK and enAsCas12a-HF1 for simultaneous cleavage of multiple sites
[0039] In this embodiment, the activity of Gs12-7MAX, Gs12-7EGK and enAsCas12a-HF1 in editing multiple different genomic sites in cells at the same time was evaluated. Gs12-7MAX, Gs12-7EGK and enAsCas12a-HF1 were co-transfected with crRNA eukaryotic expression vectors that can target 3 or 2 genes at the same time. The crRNA paired with the target nucleic acid was used to guide Gs12-7MAX, Gs12-7EGK and enAsCas12a-HF1 proteins to recognize and bind to the target nucleic acid, thereby stimulating genome cutting activity. Finally, HEK 293T cells were collected and genomic DNA was extracted, and the editing activity of the target position was analyzed by high-throughput sequencing and using CRISPResso2.
[0040] In this embodiment, the target nucleic acids selected are human DNMT1, FANCF, RUNX1 genes and EMX1, and the PAM of the target recognition site is selected as TTTV. The crRNA expression vectors that can simultaneously target three genes are designed: DNMT1-DFR-D, FANCF-DFR-F2, RUNX1-DFR-R2, and the crRNA expression vectors that can simultaneously target two genes: EMX1-EE-E1 and EMX1-EE-E2. The corresponding crRNA sequences are shown in Table 3, and the underlined regions are the targeting regions. They are respectively constructed into crRNA eukaryotic expression vectors.
[0041] Table 3. Names and corresponding sequences of crRNA
[0042] crRNA Sequence (5'-3') DFR-D AAUUUCUACUAUUGUAGAUUCUGAUGGUCCAUGUCUGUUA DFR-F2 AAUUUCUACUAUUGUAGAUUGGCGGGGUCCAGUUCCGGGA DFR-R2 AAUUUCUACUAUUGUAGAUUGCUCCGAAGGUAAAAGAAAU EE-E1 AAUUUCUACUAUUGUAGAUUUCAUCUGUGCCCCUCCCUCC EE-E2 AAUUUCUACUAUUGUAGAUUUACUUUGUCCUCCGGUUCUG
[0043] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4 Cells / well. Transfection was performed 6-8 h after plating. 1 μg of Gs12-7MAX expression plasmid plenti-Gs12-7MAX-puro, Gs12-7EGK expression plasmid plenti-Gs12-7EGK-puro eukaryotic expression vector or known enhanced enAsCas12a-HF1 expression plasmid plenti-enAsCas12a-HF1-puro, 500 ng of crRNA tandem expression vector plenti-U6-DFR-D-DFR-F2-DFR-R2-zsGreen or plenti-U6-EE-E1-EE-E2-zsGreen, which can simultaneously target two or three genes, were added to 200 μL Jetprime Buffer. Figure 3 As shown in A. Mix well with 10 μL Jetprime regent and incubate at room temperature for 10 minutes. Add the incubated mixture to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, discard the culture medium, resuspend the cells with 100 μL PBS and extract the cell genome. PCR amplify the sequence near the target site of the transfected positive cells. The PCR product was recovered and sequenced by Illumina Novaseq PE150 for amplicon sequencing, and the editing activity was analyzed by CRISPResso2.
[0044] The results are as follows Figure 3 As shown, it was found that Gs12-7MAX and Gs12-7EGK nucleases had genome editing activity regardless of whether they edited two or three sites simultaneously. In the absence of enrichment for gene editing-positive cells, the gene editing activity of Gs12-7MAX reached a maximum of about 35%, while that of Gs12-7EGK was only 28% ( Figure 3 A). In terms of average gene editing activity, the activity of Gs12-7MAX is significantly higher than that of enAsCas12a-HF1 and Gs12-7EGK, and the activity for editing multiple genes simultaneously can reach about 20% ( Figure 3 B). Therefore, the CRISPR-Gs12-7MAX system has significantly high gene editing activity.
[0045] Example 4. Detection of Indel distribution characteristics after targeted cleavage of target sites by Gs12-7MAX
[0046] In this embodiment, high-throughput sequencing and CRISPResso2 software are used to detect the distribution characteristics of Indel after directional cutting of Gs12-7MAX, Gs12-7EGK and enAsCas12a-HF1 for the target site. In this embodiment, the target nucleic acid is selected as the gene site of Examples 2 and 3, and the corresponding crRNA is shown in Tables 2 and 3. The PCR products of the above two embodiments are sequenced by Illumina Novaseq PE150, and the sequencing data are analyzed by CRISPResso2 to further evaluate the distribution and size characteristics of Indel.
[0047] The results are as follows Figure 4 As shown, after obtaining the statistics of the sequencing results of all target sites in Examples 2 and 3, further evaluation found that the gene editing Indel distribution types of Gs12-7MAX, Gs12-7EGK and enAsCas12a were basically the same ( Figure 4 A, B, C left figure), most of them are small fragment deletions (about 96%), and a small number of gene editing sites have small fragment insertions (about 4%). And the results show that after CRISPR-Gs12-7MAX technology edits the target site, the main base deletion is within 20bp, and only a small part is within 10bp. Figure 4 A, B, and C (right side).
[0048] Example 5. Evaluation of the gene editing specificity of Gs12-7MAX and enAsCas12a-HF1
[0049] This embodiment designs crRNA for the site-directed editing of Gs12-7MAX and enAsCas12a-HF1 in the above-mentioned embodiments 2 and 3, such as 6 crRNAs such as EMX1-2, EMX1-3, EMX1-4, FANCF-2, RUNX1-2 and DNMT1, and uses CRISPR-offinder software to predict 3 off-target sites for each crRNA as shown in Table 4, namely Offsite1-EMX1-2, Offsite2-EMX1-2, Offsite2-EMX1-3, Offsite1-EMX1-3, Offsite2-EMX1-3 and other 18 off-target sites, wherein the lowercase bases marked in the sequence of Table 4 are predicted off-target mismatch sites. After transfecting HEK 293T cells, the predicted off-target sites were PCR amplified and library sequenced, and the cutting efficiency was analyzed using CRISPResso2 software to evaluate the genomic cutting specificity of Gs12-7MAX and enAsCas12a-HF1.
[0050] In this example, HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8×10 4 Cells / well. After 6-8 hours of plating, transfection was performed. 1 μg of Gs12-7MAX expression plasmid plenti-Gs12-7MAX-puro or known enhanced enAsCas12a-HF1 expression plasmid plenti-enAsCas12a-HF1-puro, 500 ng of the above different crRNA expression vectors plenti-U6-crRNA-zsGreen, and 10 μL of Jetprimeregent were added to 200 μL Jetprime Buffer, and mixed by pipetting, and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded, the cells were resuspended with 100 μL PBS, and the cell genome was extracted. The PCR amplification primers corresponding to the predicted off-target sites were designed as shown in Table 4, and the genomic regions of the candidate predicted off-target sites were amplified by PCR technology. The PCR products were recovered and the amplicon was sequenced by Illumina Novaseq PE150, and the cleavage editing activity was analyzed using CRISPResso2 software.
[0051] Table 4. Predicted candidate off-target sites and corresponding PCR amplification primer sequence pairs
[0052]
[0053]
[0054]
[0055] The results are as follows Figure 5 As shown in Figure 2, high-throughput sequencing revealed that for predicted candidate off-target sites, Gs12-7MAX and enAsCas12a-HF1 had almost no detectable off-target activity ( Figure 5 A). Further comparative analysis showed that no off-target efficiency was detected at multiple predicted off-target sites, and the highest off-target efficiency was less than 1% ( Figure 5 B), Overall, the Gs12-7MAX variant was found to have low off-target efficiency and had very high specificity, similar to the enhanced and high-fidelity enAsCas12a-HF1 ( Figure 5 B). Therefore, the Gs12-7MAX variant can be used as a highly efficient gene editing tool.
[0056] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with the field can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.
Claims
1. A nuclease variant in the CRISPR / Gs12-7 system, characterized in that Includes the following proteins: I. Gs12-7MAX protein having an amino acid sequence as shown in SEQ ID NO.1, wherein the amino acid at position 157 is mutated from Glu to Arg relative to the wild-type Gs12-7 endonuclease; II. A protein having one or more amino acids substituted, deleted or added compared to the amino acid sequence shown in SEQ ID NO.1, and substantially retaining the biological function derived from the sequence.
2. A fusion protein, characterized in that Comprising the protein according to claim 1 and other modified parts.
3. A polynucleotide, characterized in that The polynucleotide is a polynucleotide encoding the endonuclease variant according to claim 1, or a polynucleotide encoding the fusion protein according to claim 2.
4. A carrier, characterized in that The vector comprises the polynucleotide according to claim 3.
5. A host cell, characterized in that The host cell comprises the polynucleotide of claim 3 or the vector of claim 4.
6. Use of the endonuclease variant according to claim 1, or the fusion protein according to claim 2, or the polynucleotide according to claim 3, or the vector according to claim 4, or the host cell according to claim 5 in gene editing.
7. A CRISPR / Gs12-7MAX gene editing system, characterized in that: It comprises the nuclease according to claim 1, or the fusion protein according to claim 2, or the polynucleotide according to claim 3, or the vector according to claim 4, or the host cell according to claim 5.
Citation Information
Patent Citations
Heat-resistant endonuclease and gene editing system mediated by heat-resistant endonuclease
CN116144631A
PAM-limitation-free endonuclease and gene editing system mediated by same
CN116286737A
Heat-resistant endonuclease and gene editing system mediated by heat-resistant endonuclease
US20240254465A1
Cited By
Application of Gs12-7MAX nuclease in targeted editing of fish genome
CN122564054A
Use of a gs12-7max nuclease in targeted genome editing in fish
CN122564054B
Endonuclease gs12-7max and gene editing system mediated thereby
WO2026061506A1
